One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents von Coney, Joseph M, McCoy, Jasmyne E, Sinha, Samriddhi Buxy, Sonbolian, Nina, Zhou, Lujia, Hull, Thomas P, Lewis, Shawn A, Miller, David G, Novak, Michael A, Pendergast, Scott D, Pham, Hang, Platt, Sean M, Rao, Llewelyn J, Schartman, Jerome P, Singerman, Lawrence J, Donkor, Richard, Fink, Margaret, Zubricky, Ryan, Karcher, Helene

Volltext

Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degeneration von Coney, Joseph M, Zubricky, Ryan, Sinha, Samriddhi Buxy, Sonbolian, Nina, Zhou, Lujia, Hull, Thomas P, Lewis, Shawn A, Miller, David G, Novak, Michael A, Pendergast, Scott D, Pham, Hang, Platt, Sean M, Rao, Llewelyn J, Schartman, Jerome P, Singerman, Lawrence J, Donkor, Richard, Fink, Margaret, McCoy, Jasmyne, Karcher, Helene

Volltext

Ciliary Neurotrophic Factor for Macular Telangiectasia Type 2: Results From a Phase 1 Safety Trial von Chew, Emily Y, Clemons, Traci E, Peto, Tunde, Sallo, Ferenc B, Ingerman, Avner, Tao, Weng, Singerman, Lawrence, Schwartz, Steven D, Peachey, Neal S, Bird, Alan C

Volltext